Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 62

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 62
---
-performance alignment.

| NEO              |     | 2024 EIP Target 
 ($)             |     |           |     | Actual EIP Payout 
 ($)               |     |           |     | Payout as a Percentage of Target 
 (%)                              |     |
| David M. Cordani |     |                 |     | 3,200,000 |     |                   |     | 2,720,000 |     |                                  |  85 |
| Brian C. Evanko  |     |                 |     | 2,000,000 |     |                   |     | 1,700,000 |     |                                  |  85 |
| Noelle K. Eder   |     |                 |     |   900,000 |     |                   |     |   972,000 |     |                                  | 108 |
| Nicole S. Jones  |     |                 |     |   900,000 |     |                   |     |   972,000 |     |                                  | 108 |
| Eric P. Palmer   |     |                 |     | 2,000,000 |     |                   |     | 1,840,000 |     |                                  |  92 |

Mr. Cordani

In early 2025, the Committee, together with the Lead Independent Director, assessed Mr. Cordani’s 2024 performance in the context of the Company’s overall performance for the year. This assessment included a review of the Company’s financial performance in 2024, strategic accomplishments to drive value for our customers, patients, clients and shareholders, as well as Mr. Cordani’s individual contributions. Following this review, the Committee made recommendations to the independent members of the Board related to Mr. Cordani’s EIP award for 2024. The independent members of the Board considered these recommendations as part of their own independent review of Mr. Cordani’s performance. More specifically, the Board considered the following factors:

Enterprise Performance. Mr. Cordani led The Cigna Group’s delivery of strong value for our customers, patients, clients and shareholders, resulting in year-over-year financial growth in a dynamic and challenging environment. These results include:

• Adjusted income from operations of $7.7 billion, adjusted income from operations per share of $27.33, and adjusted revenues of $247.1 billion.

• The return of $8.6 billion in capital to shareholders through share repurchases and dividends.

• The successful completion of a